Molecular biology of choroidal neovascularization.
VEGF plays a pivotal role in the neovascularization of the choroid in AMD. Anti-VEGF agents have been developed to target VEGF itself or its receptor signal transduction pathway, and have shown promising results in clinical trials. The combination of anti-VEGF strategies with established treatment modalities may have additional efficacy. Safe and effective drug-delivery systems are also required for the successful anti-VEGF therapies for AMD and other ocular diseases with CNV.
Lu
Ming
M
Vantage Eye Center, 622 Abbott Street, Salinas, CA 93901, USA.
Adamis
Anthony P
AP
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab; D015415:Biomarkers / Q000378:metabolism; D002829:Choroid / Q000098:blood supply; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000378:metabolism*; D018450:Disease Progression; D006801:Humans; D007267:Injections; D008967:Molecular Biology; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D015415:Biomarkers; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab